0000000000455987

AUTHOR

J. De Vocht

showing 3 related works from this author

Risk for non-AIDS-defining and AIDS-defining cancer of early versus delayed initiation of antiretroviral therapy

2021

BACKGROUND: Immediate initiation of antiretroviral therapy (ART) regardless of CD4 cell count reduces risk for AIDS and non-AIDS-related events in asymptomatic, HIV-positive persons and is the standard of care. However, most HIV-positive persons initiate ART when their CD4 count decreases below 500 × 10 9 cells/L. Consequences of delayed ART on risk for non-AIDS-defining and AIDS-defining cancer, one of the most common reasons for death in HIV, are unclear. OBJECTIVE: To estimate the long-term risk difference for cancer with the immediate ART strategy.DESIGN: Multinational prospective cohort study.SETTING: The D:A:D (Data collection on Adverse events of anti-HIV Drugs) study, which included…

MaleHIV AIDSHIV Infections0302 clinical medicineInterquartile rangeRisk FactorsNeoplasmsMedicine030212 general & internal medicineProspective StudiesProspective cohort study0303 health sciencesIncidenceAbsolute risk reductionDrugsGeneral MedicineMiddle AgedViral LoadAntiretroviral therapy3. Good healthAIDSCancer treatmentPrevention policy and public healthCohortInfectious diseasesCohort studiesFemaleViral loadAdultmedicine.medical_specialtyAnti-HIV AgentsHIV Infections/drug therapySocio-culturaleTime-to-Treatment03 medical and health sciencesAcquired immunodeficiency syndrome (AIDS)SDG 3 - Good Health and Well-beingInternal medicineInternal MedicineHumansAdverse effect030306 microbiologybusiness.industryHIVCancermedicine.diseaseCD4 Lymphocyte CountCancer.Anti-HIV Agents/therapeutic use[SDV.SPEE]Life Sciences [q-bio]/Santé publique et épidémiologiebusinessNeoplasms/epidemiologyAnnals of Internal Medicine
researchProduct

Paving the way of systems biology and precision medicine in allergic diseases: the Me DALL success story

2016

MeDALL (Mechanisms of the Development of ALLergy; EU FP7-CP-IP; Project No: 261357; 2010-2015) has proposed an innovative approach to develop early indicators for the prediction, diagnosis, prevention and targets for therapy. MeDALL has linked epidemiological, clinical and basic research using a stepwise, large-scale and integrative approach: MeDALL data of precisely phenotyped children followed in 14 birth cohorts spread across Europe were combined with systems biology (omics, IgE measurement using microarrays) and environmental data. Multimorbidity in the same child is more common than expected by chance alone, suggesting that these diseases share causal mechanisms irrespective of IgE sen…

0301 basic medicineAllergyeducation.field_of_studybusiness.industrySystems biologyImmunologyPopulationAtopic dermatitisOmicsmedicine.diseasePrecision medicine3. Good healthReview article03 medical and health sciences030104 developmental biology0302 clinical medicine030228 respiratory systemImmunologyImmunology and AllergyMedicinemedia_common.cataloged_instanceEuropean unionbusinesseducationmedia_commonAllergy
researchProduct

Paving the way of systems biology and precision medicine in allergic diseases: The MeDALL success story

2016

MeDALL Mechanisms of the Development of ALLergy; EU FP7-CP-IP; Project No: 261357; 20 (10) -2015 proposed an innovative approach to develop early indicators for the prediction, diagnosis, prevention and targets for therapy(.) MeDALL linked epidemiological, clinical and basic research using a stepwise, large-scale and integrative approach: precisely phenotyped children followed in 14 birth cohorts spread across Europe were combined with systems biology omics, IgE measurement using micro-arrays and environmental data(.) Multimorbidity in the same child is more common than expected by chance alone, suggesting that these diseases share causal mechanisms irrespective of IgE sensitisation(.) IgE …

multimorbidityBIRTH COHORTIMMUNE-RESPONSESEUROPEAN INNOVATION PARTNERSHIPCHILDHOOD ASTHMAIGE SENSITIZATIONasthmaINTEGRATED CARECHRONIC RESPIRATORY-DISEASESrhinitispolysensitizationATOPIC-DERMATITISIgEIMMUNOLOGICAL REACTIVITYIMMUNOGLOBULIN-E
researchProduct